Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Inogen, Inc.NASDAQ: INGN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $8.32M (cash outflow) rose 34.8% year over year, ahead of the -9.4% change in trailing-twelve-month net income. Sequentially, it rose 16.8% from the prior quarter. Over 3 fiscal years it compounded at -35.2% a year.
Context
- Net income amounted to 6.5% of revenue in FY2025, down 4.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$26.63M (+17.1%) for the fiscal year ending Dec 2026, a step up from the -36.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.32M+16.8% QoQ
- Last fiscal yearDec 2025
- -$22.75M-36.6% YoY
- LTMMar 2026
- -$24.9M-9.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +34.8% | -2.3% | -37.1 pp |
| 1 year | -36.6% | +17.1% | +53.7 pp |
| 3-year CAGR | -35.2% | -23.5% | +11.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (22.75M) USD
- Year-over-year change
- +36.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.75M) | +36.6% |
| FY2024 | 2024-12-31 | (35.89M) | +65.0% |
| FY2023 | 2023-12-31 | (102.45M) | -22.3% |
| FY2022 | 2022-12-31 | (83.77M) | -1222.8% |
| FY2021 | 2021-12-31 | (6.33M) | — |
Net Income vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 net income of $24.9M is the 10th largest of the 11 companies compared; the peer median is $74.93M.
- Its year-over-year change of -9.4% is the 8th highest of 10, against a peer median of +84.6%.
- Net income amounts to 7.1% of revenue for INGN, versus a peer median of 81.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $265.26M | +265.1% | +9.0% | 87.7% | |
| LTM Mar 2026 | $136.85M | +947.5% | +42.7% | 1427.2% | |
| LTM Mar 2026 | $111.13M | +30.5% | +91.6% | 17982.7% | |
| LTM Mar 2026 | $104.19M | +117.6% | +3.5% | 71.9% | |
| LTM Dec 2025 | $75.02M | +40.2% | -10.7% | 576.1% | |
| LTM Mar 2026 | $74.85M | -34.2% | -20.6% | 63.7% | |
| LTM Mar 2026 | $44.08M | — | — | 81.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M | +84.6% | +27.3% | — |
| LTM Mar 2026 | $37.25M | -24.6% | -23.6% | 46.8% | |
| LTM Mar 2026 | $24.9M | -9.4% | -35.2% | 7.1% | |
| LTM Mar 2026 | $4.24M | +113.0% | — | 9.6% | |
| Peer median (excluding INGN) | $74.93M | +84.6% | +6.2% | 81.8% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| Deferred Income Tax | 14.44M | 0 | (251K) | (1.15M) | (1.1M) |
| Stock-Based Compensation | 10.94M | 12.28M | 7.43M | 7.4M | 8.01M |
| Change in Working Capital | (20.07M) | (44.72M) | 14.27M | (4.39M) | (26.91M) |
| Accounts Receivables | (5.42M) | (51.62M) | 11.13M | (5.07M) | (14.62M) |
| Inventory | (10.78M) | (5.6M) | 7.88M | (3.54M) | (3.21M) |
| Accounts Payables | (6.48M) | 6.76M | (9.18M) | (3.41M) | 5.6M |
| Other Working Capital | 2.61M | 5.74M | 4.44M | 7.63M | (14.68M) |
| Other Non-Cash Items | 3.02M | 55.16M | 59.62M | 18.94M | 10.87M |
| Operating Cash Flow | 23.63M | (37.53M) | (3.23M) | 5.91M | (11.22M) |
| Capital Expenditures | (23.94M) | (21.22M) | (26.52M) | (17.09M) | (10.38M) |
| Acquisitions (Net) | 153K | 331K | (29.44M) | 0 | 0 |
| Purchases of Investments | (9.99M) | 0 | (26.87M) | (32.66M) | (29.83M) |
| Sales of Investments | 19.26M | 10.01M | 24M | 35.5M | 14M |
| Other Investing Activities | 0 | 0 | 0 | (1.82M) | 0 |
| Investing Cash Flow | (14.65M) | (10.88M) | (59.32M) | (13.98M) | (26.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.65M | 1.74M | 1.48M | 811K | 28.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (647K) | (1.36M) | (518K) | (546K) | (4M) |
| Financing Cash Flow | 15M | 380K | 960K | 265K | 24.18M |
| Effect of Forex Changes | (426K) | (481K) | 67K | (281K) | 846K |
| Net Change in Cash | 23.56M | (48.51M) | (61.52M) | (8.08M) | (12.4M) |
| Free Cash Flow | (302K) | (58.75M) | (29.75M) | (11.18M) | (21.6M) |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.